Xilio Therapeutics Finalizes Reverse Stock Split Proposal to Avoid Nasdaq Delisting
XLO is trading near its 52-week low of $0.573 (8.1% above the low).
Summary
Xilio Therapeutics filed a definitive proxy statement, setting a special meeting for February 23, 2026, to seek stockholder approval for a reverse stock split (1-for-2 to 1-for-30) aimed at maintaining its Nasdaq listing.
Key Events · Corporate Governance and Compliance · XLO
-
Special Meeting Scheduled for Reverse Split Vote
A special meeting of stockholders is scheduled for February 23, 2026, to vote on an amendment to the company's certificate of incorporation to effect a reverse stock split.
-
Reverse Stock Split Ratio Proposed
Stockholders will vote on a reverse stock split at a ratio within the range of 1-for-2 to 1-for-30, with the exact ratio to be determined by the board of directors.
-
Critical for Nasdaq Listing Compliance
The primary purpose of the reverse stock split is to increase the per share market price to meet Nasdaq's minimum bid price requirement and avoid delisting by the March 30, 2026 deadline.
-
Board Unanimously Recommends Approval
The board of directors unanimously recommends that stockholders vote 'FOR' the adoption and approval of the reverse stock split proposal.
Analysis · XLO · Life Sciences
This definitive proxy statement finalizes the terms for a special stockholder meeting on February 23, 2026, to vote on a reverse stock split. The company, with its stock trading significantly below $1.00, is urgently seeking approval for a reverse split (1-for-2 to 1-for-30) to meet Nasdaq's minimum bid price requirement by the March 30, 2026 deadline. While a reverse split is a critical step to avoid delisting and maintain market access, it does not address underlying operational or financial challenges. Investors should note the board's unanimous recommendation, highlighting the necessity of this action, but also be aware that there is no guarantee of sustained compliance or improved market perception post-split.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XLO was trading at $0.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $33M. The 52-week trading range was $0.57 to $1.70. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.